RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO

Published on January 13, 2026
ALISO VIEJO, Calif.—RxSight, Inc., (Nasdaq: RXST) an ophthalmic medical device company focused on providing customized vision to patients following cataract surgery, has announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025.
Continue reading on website
Other news

Kentucky optometry board loosens licensing standards, allows test substitutions

January 12, 2026
The board has waived testing requirements for years, drawing scrutiny to 21 optometrists holding licenses who did not pass one or more parts of their national exams.

Myopia May Necessitate Filtering Surgeries Later in Life, Large Study Finds

January 14, 2026
Individuals with myopia—particularly high myopia—show a significantly increased risk of developing glaucoma and requiring glaucoma surgery, according to a large population-based cohort study. Photo: Justin Schweitzer, OD. Click image to enlarge. At varying levels of severity, myopia increases the risk of developing glaucoma later in life and with that comes a greater chance